SWEDMAF Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Carina Blomstrom-Lundqvist SWEDMAF Trial.

Slides:



Advertisements
Similar presentations
INTRINSIC RV Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Brian Olshansky Inhibition of Unnecessary RV Pacing with AV.
Advertisements

Pexelizumab for the Reduction of Infarction and Mortality in Coronary Artery Bypass Graft ll (PRIMO-CABG II) Trial Presented at The American College of.
Widimsky P, Tousek P, Rokyta R, et al. Charles University Prague, CZ PRAGUE-7 Study (Hot Lines presenter)
PROTECT-AF (LAA Closure with Watchman vs Warfarin in AF and Stroke) A long-term (45-month) follow-up analysis of device therapy with Watchman vs warfarin.
Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure Presented at American College of Cardiology Scientific Sessions.
Atrial Fibrillation in Patients with Cryptogenic Stroke Gladstone DJ et al. N Engl J Med 2014; 370: Presented by Kris Huston | July 21, 2014.
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.
Ablation for Paroxysmal Atrial Fibrillation (APAF) Trial Presented at The American College of Cardiology Scientific Session 2006 Presented by Dr. Carlo.
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.
Treating to New Targets Study TNT Trial Presented at The American College of Cardiology Scientific Sessions 2005 Presented by Dr. John C. LaRosa.
Clinical Trial Results. org Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention.
Randomized Angioplasty Beta Blocker Intracoronary Trial II (RABBIT II) Presented at The American Heart Association Scientific Session 2006 Presented by.
Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE) Trial Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET LATE)
Impact of Concomitant Tricuspid Annuloplasty on Tricuspid Regurgitation Right Ventricular Function and Pulmonary Artery Hypertension After Degenerative.
Preservation Solutions, Vein Graft Patency, and Outcomes after Coronary Bypass Surgery RE Harskamp, JH Alexander, PJ Schulte, CM Brophy, MJ Mack, ED Peterson,
Value of Endothelin Receptor Inhibition with Tezosentan in Acute Heart Failure Studies VERITAS Trial Presented at The American College of Cardiology Scientific.
Specialized Atrial Fibrillation Clinic reduces cardiovascular morbidity and mortality in patients with atrial fibrillation Jeroen ML Hendriks, MSc Robert.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
Redo afib ablation John R Onufer MD FHRS
Which Early ST-Elevation Myocardial Infarction Therapy (WEST) Trial Paul W. Armstrong, WEST Steering Committee Published in The European Heart Journal.
Safety of Cyclooxygenase-2 (COX-2) inhibitors, Valdecoxib and Parecoxib, versus Placebo for Post CABG Pain Management Presented at American College of.
Occluded Artery Trial (OAT) Presented at The American Heart Association Scientific Session 2006 Presented by Dr. Judith S. Hochman OAT Trial.
Asklepios Klink St. Georg, Hamburg
Safety and Efficacy of Intravenous Enoxaparin in Elective Percutaneous Coronary Intervention: an International Randomized Evaluation (STEEPLE) Presented.
Trial Design Issues Associated with Evaluation of Distal Protection Devices in Diseased Saphenous Vein Grafts Bram D. Zuckerman, MD, FACC Medical Officer,
The Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented.
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.
Atorvastatin for Reduction of Myocardial Dysrhythmias After Cardiac Surgery Trial Presented at The American College of Cardiology Scientific Sessions March.
Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions Trial Presented at The American College of Cardiology Scientific Session 2006.
Preoperative Hemoglobin A1c and the Occurrence of Atrial Fibrillation Following On-pump Coronary Artery Bypass surgery in Type-2 Diabetic Patients Akbar.
EVEREST II Study Design Multicenter Randomized in a 2:1 ratio to either percutaneous or conventional surgery for the repair or replacement of the mitral.
A-4 Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Pierre Jais Atrial Fibrillation Ablation vs. Antiarrhythmic Drugs Trial.
Perindopril Remodeling in Elderly with Acute Myocardial Infarction PREAMIPREAMI Presented at The European Society of Cardiology Hot Line Session, September.
Prospective Evaluation of EECP in Congestive Heart Failure (PEECH) Trial PEECH Trial Presented at The American College of Cardiology Scientific Sessions.
Ischemia Management with Accupril Post Bypass Graft via Inhibition of Angiotensin Converting Enzyme IMAGINEIMAGINE Presented at The European Society of.
European trial on reduction of cardiac events with perindopril in stable coronary artery disease Presented at European Society of Cardiology 2003 EUROPA.
Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) Trial Presented at The American College of Cardiology Scientific Session.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Clinical Trial Results. org Impact of Epicardial Anterior Fat Pad Retention on Postcardiothoracic Surgery Atrial Fibrillation Incidence: The AFIST-III.
Clinical Trial Results. org ILLUSTRATE Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Steven E.
R2. 최태웅 / Pf. 김진배. BACKGROUND  Ischemic stroke : leading causes of death and disability : cause remains unexplained after routine evaluation → Cryptogenic.
Assessment of the Safety and Efficacy of a New Treatment Strategy for Acute Myocardial Infarction (ASSENT-4 PCI) Trial ASSENT- 4 PCI Trial Presented at.
Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation Jens Cosedis Nielsen, M.D., D.M.Sc., Arne Johannessen, M.D., D.M.Sc., Pekka.
The American College of Cardiology Presented by Dr. Adnan Kastrati
Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.
Is There a Need to Address AF in patients Undergoing Valve Surgery?
The European Society of Cardiology Presented by Dr. Bo Lagerqvist
Atrial fibrillation II: rationale for surgical treatment
Successful Cox Maze Procedure During Mitral Valve Surgery Restores Patient Survival Without Increasing Operative Risk Niv Ad, MD Chief, Cardiac Surgery.
Presented by Dr. Leif Thuesen
(p for noninferiority = )
MAGIC-AF Trial design: Patients with persistent atrial fibrillation (AF) and remaining in AF after pulmonary vein isolation alone were randomized to either.
Catheter Ablation for the Cure of Atrial Fibrillation Study
Mitral Valve Disease.
The American College of Cardiology Presented by Dr. Raimund Erbel
Sildenafil for Improving Outcomes in Patients With Corrected Valvular Heart Disease and Persistent Pulmonary Hypertension: A Multicenter, Double-Blind,
AFACT Trial design: Patients with long-standing atrial fibrillation were randomized to ganglion plexus ablation (n = 117) vs. control (n = 123) on top.
Risk Factor Modification
Stavros Stavrakis et al. JACEP 2015;1:1-13
Patrick T. O'Gara, MD, MACC, FAHA, Thoralf M. Sundt, MD, Michael A
Atrial fibrillation II: rationale for surgical treatment
Physical Counterpressure Maneuver (PC) Trial
ARISE Trial Aggressive Reduction of Inflammation Stops Events
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
Sirolimus Stent vs. Bare Stent in Acute Myocardial Infarction Trial
Randomized study of surgery for patients with permanent atrial fibrillation as a result of mitral valve disease  Gustavo Glotz de Lima, MD, PhD, Renato.
Presentation transcript:

SWEDMAF Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Carina Blomstrom-Lundqvist SWEDMAF Trial

SWEDMAF Trial: Background AF is present in a majority of patients undergoing mitral-valve surgery and persists in 80% to 90% of patients after surgery.AF is present in a majority of patients undergoing mitral-valve surgery and persists in 80% to 90% of patients after surgery. The goal of the trial was to evaluate mitral valve surgery with pulmonary vein isolation (PVI) using epicardial cryoablation compared with mitral valve surgery alone among patients with permanent atrial fibrillation (AF) and mitral valve disease.The goal of the trial was to evaluate mitral valve surgery with pulmonary vein isolation (PVI) using epicardial cryoablation compared with mitral valve surgery alone among patients with permanent atrial fibrillation (AF) and mitral valve disease. AF is present in a majority of patients undergoing mitral-valve surgery and persists in 80% to 90% of patients after surgery.AF is present in a majority of patients undergoing mitral-valve surgery and persists in 80% to 90% of patients after surgery. The goal of the trial was to evaluate mitral valve surgery with pulmonary vein isolation (PVI) using epicardial cryoablation compared with mitral valve surgery alone among patients with permanent atrial fibrillation (AF) and mitral valve disease.The goal of the trial was to evaluate mitral valve surgery with pulmonary vein isolation (PVI) using epicardial cryoablation compared with mitral valve surgery alone among patients with permanent atrial fibrillation (AF) and mitral valve disease. Presented at HRS 2006

SWEDMAF Trial: Study Design Presented at HRS 2006  Primary Endpoint: Sinus rhythm at 6 months  Secondary Endpoint: Sinus rhythm at 12 months; quality of life at 6 and 12 months  Primary Endpoint: Sinus rhythm at 6 months  Secondary Endpoint: Sinus rhythm at 12 months; quality of life at 6 and 12 months Mitral valve surgery with PVI using cryoablation n=30 Mitral valve surgery with PVI using cryoablation n=30 65 patients, age years, ECG documented AF for at least 3 months, clinical indication for mitral valve surgery Randomized. 22% female, mean age 65 years, mean follow-up 1 year Surgeons were un-blinded to treatment assignment but both the patient and the cardiologists remained blinded 65 patients, age years, ECG documented AF for at least 3 months, clinical indication for mitral valve surgery Randomized. 22% female, mean age 65 years, mean follow-up 1 year Surgeons were un-blinded to treatment assignment but both the patient and the cardiologists remained blinded Mitral valve surgery alone n=35 Mitral valve surgery alone n=35

SWEDMAF Trial: Intraoperative ECC Time SWEDMAF Trial: Intraoperative ECC Time Presented at HRS 2006 Intra-operative ECC time was longer in the mitral valve surgery with cryoablation group than the surgery alone group (146 min vs. 119 min, p=0.0015), driven by the 21 minute cryoablation procedure time.Intra-operative ECC time was longer in the mitral valve surgery with cryoablation group than the surgery alone group (146 min vs. 119 min, p=0.0015), driven by the 21 minute cryoablation procedure time. Intraoperative ECC Time p= Minutes

SWEDMAF Trial: Primary Endpoint Presented at HRS 2006 The primary endpoint of sinus rhythm at 6 months occurred more frequently in the mitral valve surgery with cryoablation group compared with the mitral valve surgery alone group (73% vs. 46%, p=0.024).The primary endpoint of sinus rhythm at 6 months occurred more frequently in the mitral valve surgery with cryoablation group compared with the mitral valve surgery alone group (73% vs. 46%, p=0.024). Primary endpoint of sinus rhythm at 6 months p=0.024

SWEDMAF Trial: Secondary Endpoint Presented at HRS 2006 Secondary endpoint of sinus rhythm at 12 monthswas maintained (73% vs. 49%, p=0.042)Secondary endpoint of sinus rhythm at 12 months was maintained (73% vs. 49%, p=0.042) Secondary endpoint of Sinus Rhythm at 12 Months p=0.042

SWEDMAF Trial: Adverse Events Adverse events were relatively infrequent, with no deaths in the surgery alone group and 2 deaths in the surgery with cryoablation group, one of which was due to cancer and one due to heart failure.Adverse events were relatively infrequent, with no deaths in the surgery alone group and 2 deaths in the surgery with cryoablation group, one of which was due to cancer and one due to heart failure. Bleeding requiring re-operation occurred in 1 patient in the surgery alone group and 3 patients in the cryoablation group.Bleeding requiring re-operation occurred in 1 patient in the surgery alone group and 3 patients in the cryoablation group. Presented at HRS 2006

SWEDMAF Trial: Results Among patients with permanent atrial fibrillation and mitral valve disease, mitral valve surgery with pulmonary vein isolation using cryoablation was associated with higher rates of sinus rhythm at 6 months compared with mitral valve surgery without cryoablation.Among patients with permanent atrial fibrillation and mitral valve disease, mitral valve surgery with pulmonary vein isolation using cryoablation was associated with higher rates of sinus rhythm at 6 months compared with mitral valve surgery without cryoablation. Presented at HRS 2006

SWEDMAF Trial: Summary Surgery with cryoablation restored sinus rhythm and maintained sinus rhythm more so than surgery alone, with few adverse events.Surgery with cryoablation restored sinus rhythm and maintained sinus rhythm more so than surgery alone, with few adverse events. While the present study demonstrated benefit of cryoablation with mitral valve surgery, data from the present trial do not provide information to the effect of cryoablation with coronary bypass surgery.While the present study demonstrated benefit of cryoablation with mitral valve surgery, data from the present trial do not provide information to the effect of cryoablation with coronary bypass surgery. The long-term benefit of cryoablation drying cardiac surgery for atrial fibrillation suppression remains to be evaluatedThe long-term benefit of cryoablation drying cardiac surgery for atrial fibrillation suppression remains to be evaluated Surgery with cryoablation restored sinus rhythm and maintained sinus rhythm more so than surgery alone, with few adverse events.Surgery with cryoablation restored sinus rhythm and maintained sinus rhythm more so than surgery alone, with few adverse events. While the present study demonstrated benefit of cryoablation with mitral valve surgery, data from the present trial do not provide information to the effect of cryoablation with coronary bypass surgery.While the present study demonstrated benefit of cryoablation with mitral valve surgery, data from the present trial do not provide information to the effect of cryoablation with coronary bypass surgery. The long-term benefit of cryoablation drying cardiac surgery for atrial fibrillation suppression remains to be evaluatedThe long-term benefit of cryoablation drying cardiac surgery for atrial fibrillation suppression remains to be evaluated Presented at HRS 2006